74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Clearside Biomedical Inc
Closed
0.83 5.06
Overview
Share price change
24h
Min
0.78
Max
0.84
Income | 383K -7.3M |
|---|---|
Sales | -732K 306K |
EPS | -0.1 |
Profit margin | -2,387.582 |
Employees | 32 |
EBITDA | 508K -4.6M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +625% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | -12M 66M |
|---|---|
Previous open | -4.23 |
Previous close | 0.83 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Clearside Biomedical Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Clearside Biomedical Inc Forecast
Price Target
By TipRanks
625% upside
12 Months Forecast
Average 5.8 USD 625%
High 8 USD
Low 4 USD
Based on 5 Wall Street analysts offering 12 month price targets forClearside Biomedical Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
